Get the Stockscreener App
11.66
1.13%
0.13
After Hours:
11.66
Urogen Pharma Ltd Stock (URGN) Latest News
Transitional Cell Carcinoma Treatment Market Size in 7MM - openPR
UroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Recommendation of “Buy” from Analysts - Defense World
HC Wainwright Expects Reduced Earnings for UroGen Pharma - Defense World
(URGN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Urogen pharma outlines $1B revenue potential for UGN-102 with June 2025 launch target - MSN
UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strat - GuruFocus.com
UroGen Pharma (NASDAQ:URGN) Price Target Cut to $55.00 by Analysts at HC Wainwright - Defense World
UroGen Pharma stock target cut to $55 at H.C. Wainwright By Investing.com - Investing.com Australia
UroGen Pharma stock target cut to $36 at Raymond James By Investing.com - Investing.com Australia
UroGen Pharma stock target cut to $36 at Raymond James - Investing.com India
UroGen Pharma stock target cut to $55 at H.C. Wainwright - Investing.com India
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2024 Earnings Call Transcript - Insider Monkey
UroGen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital - Defense World
UroGen Pharma Reports Strong Pipeline Progress and Revenue Growth - TipRanks
UroGen Pharma Ltd. SEC 10-K Report - TradingView
Earnings call transcript: UroGen Pharma Q4 2024 reports mixed results By Investing.com - Investing.com South Africa
UroGen Pharma shares fall as Q4 results miss estimates By Investing.com - Investing.com South Africa
UroGen Pharma shares fall as Q4 results miss estimates - Investing.com India
Earnings call transcript: UroGen Pharma Q4 2024 reports mixed results - Investing.com India
Urogen Pharma Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Urogen Pharma reports wider-than-expected fourth-quarter loss -March 10, 2025 at 10:56 am EDT - Marketscreener.com
Oppenheimer & Co. Inc. Acquires Shares of 11,875 UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma earnings missed by $0.03, revenue fell short of estimates - Investing.com Australia
UroGen Pharma Posts Wider Loss In Q4Quick Facts - Nasdaq
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102 - Joplin Globe
Rhumbline Advisers Has $546,000 Position in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph
UroGen Pharma Ltd. to Host Earnings Call - ACCESS Newswire
UroGen Strengthens Jelmyto Commercialization: Key Details on New Team RSU Package - StockTitan
UroGen Pharma (URGN) to Release Earnings on Thursday - Defense World
BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight - GlobeNewswire Inc.
How to Take Advantage of moves in (URGN) - Stock Traders Daily
UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025 - StockTitan
UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from HC Wainwright - Defense World
Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now? - Yahoo Finance UK
UroGen stock holds Buy rating, $64 target from H.C. Wainwright By Investing.com - Investing.com South Africa
UroGen stock holds Buy rating, $64 target from H.C. Wainwright - Investing.com
UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference - BioSpace
Can UroGen's Next Move Transform Urothelial Cancer Treatment? Key Insights Coming at TD Cowen - StockTitan
UroGen acquires IconOVir’s oncolytic virus assets - Yahoo Finance
UroGen Pharma (NASDAQ:URGN) Coverage Initiated at LADENBURG THALM/SH SH - Defense World
UroGen Plots Expansion, Brings In A New Asset - Insights
Low-Gade Upper Tract Urothelial Cancer Market on Track for Major - openPR
UroGen acquires oncolytic virus, expands cancer treatment options By Investing.com - Investing.com Nigeria
UroGen Pharma Acquires Oncolytic Virus From IconOVir Bio -February 20, 2025 at 10:58 am EST - Marketscreener.com
UroGen stock in focus after IconOVir deal (URGN:NASDAQ) - Seeking Alpha
UroGen acquires oncolytic virus, expands cancer treatment options - Investing.com India
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):